AIM ImmunoTech Inc. (AIM) stock forecast & analysis
0.2260
NYSE American · USD
Down: -0.0324, -12.5%
1 analysis
- Open
- 0.3709
- Previous close
- 0.2584
- Day range
- 0.2015 – 0.3711
- 52-week range
- 0.1900 – 2.89
- Volume (shares)
- 124.55M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 30.44M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.19
- Market cap
- 6.88M
Market Scanner’s AI analysis of AIM ImmunoTech Inc. (AIM), updated September 2026: AIM ImmunoTech's new patent for Rintatolimod and Pembrolizumab combination bolsters oncology position amid mixed technical indicators.
Summary
AIM ImmunoTech's new patent for Rintatolimod and Pembrolizumab combination bolsters oncology position amid mixed technical indicators.
Recent analyses for AIM ImmunoTech Inc. covered a new U.S. patent for its Rintatolimod and Pembrolizumab combination, extending intellectual property protection through 2039. Financial reports indicated a 4% year-over-year revenue increase, with sufficient liquidity despite negative profit and operating margins. Market analysis showed the stock trading below key moving averages, with a neutral RSI and bearish MACD, though a high MFI suggested strong buying pressure.
AIM news & sentiment
News coverage highlighted a significant U.S. patent award for AIM ImmunoTech's Rintatolimod combination therapy, bolstering its oncology market standing. Social media discussion was not covered in the provided notes.
AIM technical picture
The stock traded below its 50-day and 200-day moving averages, with short-term momentum also below the current price. While the RSI was neutral and the MACD indicated bearish momentum, a high MFI suggested strong buying pressure, and the price neared the lower Bollinger Band.
Fundamentals
AIM ImmunoTech Inc. reported a 4% year-over-year revenue increase. The company maintained sufficient liquidity with strong current and quick ratios, though trailing twelve-month profit and operating margins were negative.
Factors discussed — upside
- Secured U.S. patent for Rintatolimod (Ampligen®) in combination with Pembrolizumab (Keytruda®) through 2039.
- Quarterly revenue increased by 4% year-over-year.
- Sufficient liquidity with a current ratio of 2.109 and quick ratio of 2.015.
- Total cash of $9.964 million as of June 30, 2026.
- High Money Flow Index (MFI) at 96.89 suggesting strong buying pressure.
Factors discussed — risks
- Negative Profit Margin of 0% and Operating Margin of -135.1% for the trailing twelve months.
- Stock price trading below the 50-day and 200-day Simple Moving Averages.
- Short-term momentum indicated by EMA 10 below the current price.
- MACD is below zero, indicating bearish momentum.
- Intellectual Property
- Oncology Market
- Financial Liquidity
- Technical Indicators
Summary updated .
AIM technical indicators
Common technical indicators for AIM, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.27 | Price below |
| 10-day exponential moving average | 0.25 | Price below |
| Relative strength index (14-day) | 41.02 | Neutral |
| MACD line (12/26/9) | -0.0088 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.22 – 0.29 | Price inside the bands |
Analyses
Recent AIM.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for AIM ImmunoTech Inc.?
- The bull case for AIM ImmunoTech centers on its secured U.S. patent for a combination therapy through 2039, coupled with a 4% year-over-year revenue increase and strong liquidity metrics. Analyses also noted high buying pressure indicated by the Money Flow Index.
- What are the risks for AIM ImmunoTech Inc.?
- Risks discussed for AIM ImmunoTech include negative profit and operating margins over the trailing twelve months, with the stock price trading below key moving averages and exhibiting bearish momentum on the MACD.
- Is AIM ImmunoTech Inc. bullish or bearish?
- Recent AI analyses of AIM ImmunoTech Inc. examined factors on both sides. Discussed upside: The bull case for AIM ImmunoTech centers on its secured U.S. patent for a combination therapy through 2039, coupled with a 4% year-over-year revenue increase and strong liquidity metrics. Analyses also noted high buying pressure indicated by the Money Flow Index. Discussed risks: Risks discussed for AIM ImmunoTech include negative profit and operating margins over the trailing twelve months, with the stock price trading below key moving averages and exhibiting bearish momentum on the MACD. These are descriptive observations, not a recommendation.
- What is the latest sentiment on AIM ImmunoTech Inc.?
- News coverage highlighted a significant U.S. patent award for AIM ImmunoTech's Rintatolimod combination therapy, bolstering its oncology market standing. Social media discussion was not covered in the provided notes.
- Bundles used
- gemini-low-v2
Run a fresh AIM.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every AIM.US report already in the library